- Home
- EXPI vs XERS Comparison
EXPI vs XERS Comparison
Compare EXPI & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EXPI | XERS |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EXPI | XERS |
|---|---|---|
| Price | $6.76 | $6.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $9.75 | ★ $10.83 |
| AVG Volume (30 Days) | 921.3K | ★ 1.6M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $500,147,681.00 | $49,590,000.00 |
| Revenue This Year | $6.26 | $34.37 |
| Revenue Next Year | $5.50 | $22.86 |
| P/E Ratio | ★ N/A | $638.48 |
| Revenue Growth | ★ 220.39 | 142.67 |
| 52 Week Low | $5.66 | $4.30 |
| 52 Week High | $12.23 | $10.08 |
Technical Indicators
Market Signals| Indicator | EXPI | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 60.03 | 49.57 |
| Support Level | $5.68 | $5.79 |
| Resistance Level | $6.87 | $6.41 |
| Average True Range (ATR) | 0.23 | 0.32 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 81.56 | 28.51 |
Price Performance
Historical ComparisonAbout EXPI eXp World Holdings Inc.
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.